154 related articles for article (PubMed ID: 37149142)
21. A qualitative examination of naloxone access in three states: Connecticut, Kentucky, and Wisconsin.
Spector AL; Galletly CL; Christenson EA; Montaque HDG; Dickson-Gomez J
BMC Public Health; 2022 Jul; 22(1):1387. PubMed ID: 35854278
[TBL] [Abstract][Full Text] [Related]
22. "I don't go to funerals anymore": how people who use opioids grieve drug-related death in the US overdose epidemic.
Schlosser AV; Hoffer LD
Harm Reduct J; 2022 Oct; 19(1):110. PubMed ID: 36183109
[TBL] [Abstract][Full Text] [Related]
23. Legal requirements and recommendations to prescribe naloxone.
Haffajee RL; Cherney S; Smart R
Drug Alcohol Depend; 2020 Apr; 209():107896. PubMed ID: 32058248
[TBL] [Abstract][Full Text] [Related]
24. "They're not doing enough.": women's experiences with opioids and naloxone in Toronto.
Macleod ER; Tajbakhsh I; Hamilton-Wright S; Laliberte N; Wiese JL; Matheson FI
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):26. PubMed ID: 33743756
[TBL] [Abstract][Full Text] [Related]
25. Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals.
Pham S; Haigh A; Barrett E
J Addict Med; 2022 Jan-Feb 01; 16(1):e48-e51. PubMed ID: 33758118
[TBL] [Abstract][Full Text] [Related]
26. Racial/ethnic disparities in opioid overdose prevention: comparison of the naloxone care cascade in White, Latinx, and Black people who use opioids in New York City.
Khan MR; Hoff L; Elliott L; Scheidell JD; Pamplin JR; Townsend TN; Irvine NM; Bennett AS
Harm Reduct J; 2023 Feb; 20(1):24. PubMed ID: 36841763
[TBL] [Abstract][Full Text] [Related]
27. Regional and temporal effects of naloxone access laws on opioid overdose mortality.
Cataife G; Dong J; Davis CS
Subst Abus; 2021; 42(3):329-338. PubMed ID: 31951788
[TBL] [Abstract][Full Text] [Related]
28. Attitude changes following short-form opioid overdose video education: a pilot study.
Galiher MV; Huffman M
Harm Reduct J; 2022 Oct; 19(1):114. PubMed ID: 36241995
[TBL] [Abstract][Full Text] [Related]
29. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment.
Bounthavong M; Suh K; Christopher MLD; Veenstra DL; Basu A; Devine EB
Res Social Adm Pharm; 2020 Aug; 16(8):1033-1040. PubMed ID: 31706950
[TBL] [Abstract][Full Text] [Related]
30. Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System, 2019.
Quinn K; Kumar S; Hunter CT; O'Donnell J; Davis NL
Drug Alcohol Depend; 2022 Jun; 235():109467. PubMed ID: 35461083
[TBL] [Abstract][Full Text] [Related]
31. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
[TBL] [Abstract][Full Text] [Related]
32. Characterizing and combating the opioid epidemic in the Los Angeles County jail system.
Tran NT; Muradian IK; Qureshi N; Singh J; Henderson SO
J Subst Use Addict Treat; 2023 Apr; 147():208984. PubMed ID: 36841073
[TBL] [Abstract][Full Text] [Related]
33. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
34. Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder.
Jones JD; Campbell AN; Brandt L; Castillo F; Abbott R; Comer SD
Subst Abus; 2021; 42(4):407-411. PubMed ID: 32814002
[No Abstract] [Full Text] [Related]
35. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
Adeosun SO
J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
[TBL] [Abstract][Full Text] [Related]
36. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
Holmén E; Hammarberg A; Kåberg M; Storbjörk J
Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
[TBL] [Abstract][Full Text] [Related]
37. Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.
Abell-Hart K; Rashidian S; Teng D; Rosenthal RN; Wang F
JMIR Public Health Surveill; 2022 Apr; 8(4):e32133. PubMed ID: 35412467
[TBL] [Abstract][Full Text] [Related]
38. Integration of Pharmacy Student Interns into a Naloxone Telephone Outreach Service.
Rothbauer K; Genisot A; Frey T; JohnsonPharmacy William S Middleton Memorial Veterans Hospital D
J Pain Palliat Care Pharmacother; 2022 Dec; 36(4):208-215. PubMed ID: 35997489
[TBL] [Abstract][Full Text] [Related]
39. Neighborhood and Individual Disparities in Community-Based Naloxone Access for Opioid Overdose Prevention.
Nesoff ED; Meisel ZF; Saeed H; Martins SS
J Urban Health; 2024 Feb; 101(1):64-74. PubMed ID: 38196059
[TBL] [Abstract][Full Text] [Related]
40. [First Aid Training for Drug Overdose in Opioid Addicts and Provision of Take-Home Naloxone on Release from Prison: Feasibility Study from the Bavarian Model Project].
Wodarz-von Essen HJ; Wolstein J; Pogarell O; Wodarz N
Gesundheitswesen; 2023 Jun; 85(6):568-572. PubMed ID: 36126950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
